Karen Jay

JP Morgan's biotech analysts Cory Kasimov, Mona Ashiya, and Karen Jay rate Ariad Pharmaceuticals (NASDAQ: ARIA) Overweight. Ariad's updated Phase I results for new cancer drug AP-23534 were presented on 6/3, and were promising. There were no signals for safety issue either. Based on these results,...

William Blair & Company analysts John Sonnier, Timothy Lugo and Karen Jay maintained their Outperform rating for shares of Nektar Therapeutics (Nasdaq: NKTR). The analysts mentioned the many products in the company's pipeline and its strong balance sheet as reasons for their positive rating for...